Objective To evaluate the treatment outcome and prognostic factors in patients with grade Ⅲ/IV glioma following postoperative chemoradiotherapy. Methods A retrospective analysis was performed on the medical records of 119 patients with grade Ⅲ/IV glioma who received treatment in our hospital from January 2007 to April 2012. Of the 119 patients, 49 received radiotherapy alone, 21 received radiotherapy combined with nitrosoureas, and 49 received radiotherapy combined with temozolomide. The Kaplan-Meier method was used to calculate overall survival (OS) rates and recurrence rates. The Cox regression model was used for multivariate prognostic analysis. Results The follow-up rate was 94.1%. Fifty-three patients were followed up for at least 1 year, and 10 for at least 2 years. The overall recurrence rate was 69.7%. The 1-and 2-year OS rates were 44.5% and 8.4%, respectively. The multivariate analysis showed that age, presence or absence of seizures before surgery, extent of tumor resection, and radiotherapy plus concurrent and adjuvant temozolomide were the main prognostic factors for tumor recurrence (P=0.002, 0.005, 0.000, and 0.000). The above factors and the pathological grade of tumor were the independent prognostic factors for patients′ survival (P=0.006, 0.010, 0.000, 0.000, and 0.001). Conclusions Postoperative radiotherapy plus concurrent and adjuvant temozolomide produce a good clinical effect in patients with grade Ⅲ/IV glioma. Age of<60 years, no seizures before surgery, total tumor resection, and pathological grade Ⅲ of tumor are the favorable prognostic factors for the long-term survival in patients with malignant glioma.
LI Meng-yan,SHANG Ge,ZHAO Hua-rong et al. Prognostic analysis of postoperative chemoradiotherapy in patients with grade Ⅲ/IV glioma[J]. Chinese Journal of Radiation Oncology, 2013, 22(5): 383-385.
LI Meng-yan,SHANG Ge,ZHAO Hua-rong et al. Prognostic analysis of postoperative chemoradiotherapy in patients with grade Ⅲ/IV glioma[J]. Chinese Journal of Radiation Oncology, 2013, 22(5): 383-385.
[1]肖建平.星形胶质细胞瘤//谷铣之,殷蔚伯,余子豪,等.肿瘤放射治疗学. 4版.北京:中国协和医科大学出版社,2008:1122-1123. [2]Central Brain Tumor Registry of the United States (CBTRUS). CBTRUS statistical report:pimary brain and central nervous system tumors diagnosed in the United States in 2004—2006.Hinsdale:CBTRUS,2010. [3]Ashby LS, Ryken TC. Management of malignant glioma:steady progress with multimodal approaches. Neurosurg Focus,2006,20:E3. [4]Wisoff JH, Boyett JM, Berger MS, et al. Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood:a report of the children′s Cancer Group trial no. CCG-945. J Neurosurg,1998,89:52-59. [5]Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol,2008,26:1338-1345. [6]杜谋选,袁军.影响人脑胶质瘤的预后因素.中华神经医学杂志,2005,4:145-148. [7]Stewart LA. Chemotherapy in adult high-grade glioma:a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet,2002,359:1011-1018. [8]Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade gliomas:the impact of the extent of resection on quality of life and survival. Neurosurgery,2005,57:495-504. [9]Prestwich RJ, Sivapalasunrtharam A, Johnston C, et al. Survival in high-grade glioma:a study of survival in patients unfit for or declining radiotherapy. Clin Oncol (R Coll Radiol),2005,7:133-137. [10]Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. Cochrane Database Syst Rev,2011,(3):CD007294. [11]Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med,2005,352:987-996. [12]Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase Ⅲ study:5-year analysis of the EORTC-NCIC trial. Lancet Oncol,2009,10:459-466.